4.7 Article

p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective IκB Kinase Inhibitor BMS-345541

Journal

CLINICAL CANCER RESEARCH
Volume 15, Issue 8, Pages 2767-2776

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-08-2382

Keywords

-

Categories

Funding

  1. Ministerio de Educacion y Ciencia [SAF 06/8850]
  2. Redes Tematicas de Investigacion Cooperativa de Cancer [RED 2006-20-014]
  3. Generalitat de Catalunya A predoctoral fellowship
  4. Instituto de Salud Carlos III Miguel Servet research
  5. Instituto de Salud Carlos III Sara Borrell
  6. (Ministerio de Educacion y Ciencia)

Ask authors/readers for more resources

Purpose: Constitutive nuclear factor-kappa B (NF-kappa B) activation has been implicated in the pathogenesis of chronic lymphocytic leukemia (CLL). Our purpose was to characterize the molecular mechanisms underlying for the selective I kappa B kinase inhibitor BMS-345541 in CLL cells together with the analysis of its combination with several antineoplasic drugs. Experimental Design: Primary cells from 34 CLL patients were incubated with different doses of BMS-345541. NF-kappa B DNA-binding activity was analyzed by ELISA-based kits and the characterization of the apoptotic pathway was done by flow cytometry, immunoblotting, quantitative reverse transcription-PCR, and immunofluorescence techniques. Results: BMS-345541 selectively induced apoptosis in CLL cells in the low micromolar range irrespective of p53 status. Noteworthy, the high ZAP-70 group was significantly more sensitive to BMS-345541 than the low ZAP-70 group, in correlation with high levels of p65 phosphorylation and DNA-binding activity. Following NF-kappa B inhibition, BMS-345541 led to induction of the mitochondrial apoptotic pathway and activation of both caspase-dependent and caspase-independent factors. Moreover, BMS-345541-induced apoptosis was accompanied by down-regulation of several antiapoptotic NF-kappa B-target genes, including both BCL2 family members and apoptotic endogenous inhibitors. In addition, we showed a strong synergism between BMS-345541 and conventional chemotherapeutics such as mitoxantrone and dexamethasone as well as with new promising drugs such as the BH3-mimetic GX15-070/Obatoclax or the anti-TRAIL-R1 monoclonal antibody mapatumumab. Conclusions: These data confirm that NF-kappa B is a relevant target in CLL and indicate that inhibitors of I kappa B kinase, alone or in combination, represent a novel therapeutic strategy for the treatment of CLL patients, especially for the group with high ZAP-70.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

Miguel A. Galindo-Campos, Nura Lutfi, Sarah Bonnin, Carlos Martinez, Talia Velasco-Hernandez, Violeta Garcia-Hernandez, Juan Martin-Caballero, Coral Ampurdanes, Ramon Gimeno, Lluis Colomo, Gael Roue, Guillaume Guilbaud, Francoise Dantzer, Pilar Navarro, Matilde Murga, Oscar Fernandez-Capetillo, Anna Bigas, Pablo Menendez, Julian E. Sale, Jose Yelamos

Summary: Dysregulation of the c-Myc oncogene is linked to aggressive tumor progression, and PARP-1 and PARP-2 have opposing influence in c-Myc-driven B-cell lymphoma. PARP-1 deficiency accelerates lymphomagenesis, while genetic deletion of PARP-2 prevents B-cell lymphoma. These findings provide important insights for the design of new PARP-centered therapeutic strategies.

BLOOD (2022)

Review Biochemistry & Molecular Biology

Histone Modifications and Their Targeting in Lymphoid Malignancies

Miranda Fernandez-Serrano, Rene Winkler, Juliana C. Santos, Marguerite-Marie Le Pannerer, Marcus Buschbeck, Gael Roue

Summary: In lymphoid neoplasms, malignant transformation is often associated with somatic mutations in B cells affecting the epigenetic machinery. Consequential alterations in histone modifications lead to disease-specific changes in transcriptional programs. Therapeutic strategies targeting histone methylation and acetylation show promise in improving the prognosis of lymphoma patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes

Silvia Saumell, Miranda Fernandez-Serrano, Alba Mesa, Felix Lopez-Cadenas, Leonor Arenillas, Ana Alfonso, Maria Julia Montoro, Antonieta Molero, Pilar Leoz, Victoria Riego, Laura Gallur, Olga Salamero, Mayda Navarrete, Barbara Tazon-Vega, Margarita Ortega, Oscar Reig, Gael Roue, Xavier Calvo, Felipe Prosper, Maria Diez-Campelo, David Valcarcel

Summary: The presence of Micromegakaryocytes (microMKs) in MDS patients indicates poorer outcomes, including lower overall survival rate and higher risk of progression to AML. Additionally, incorporating microMKs into the IPSS-R score can improve accuracy, leading to reclassification of some patients into higher-risk groups.

LEUKEMIA & LYMPHOMA (2022)

Article Oncology

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Matthew Salmon, Helen E. White, Hana Zizkova, Andrea Gottschalk, Eliska Motlova, Nuno Cerveira, Dolors Colomer, Daniel Coriu, Georg N. Franke, Enrico Gottardi, Barbara Izzo, Tomas Jurcek, Thomas Lion, Vivien Schaefer, Claudia Venturi, Paolo Vigneri, Magdalena Zawada, Jan Zuna, Lenka Hovorkova, Jitka Koblihova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Adela Benesova, Vaclava Polivkova, Daniela Zackova, Jiri Mayer, Ingo Roeder, Ingmar Glauche, Thomas Ernst, Andreas Hochhaus, Katerina Machova Polakova, Nicholas C. P. Cross

Summary: This study found that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. Technical analysis revealed a slight difference in the amplification ratio and efficiency between the two transcript types, resulting in variations in estimates of residual disease. These findings suggest that the choice of transcript type should be considered for optimal patient management.

LEUKEMIA (2022)

Letter Oncology

Response to The WHO classification of haematolymphoid tumours (Editorial)

Steven H. Swerdlow, Elias Campo, Daniel A. Arber, Mario Cazzola, James R. Cook, Hartmut Doehner, Martin Dreyling, Robert P. Hasserjian, Elaine S. Jaffe, Attilio Orazi, Leticia Quintanilla-Martinez, David W. Scott, Ayalew Tefferi, Jane N. Winter, Andrew D. Zelenetz

LEUKEMIA (2022)

Article Oncology

Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes

Sandra Castano-Diez, Monica Lopez-Guerra, Cristina Bosch-Castaneda, Alex Bataller, Paola Charry, Daniel Esteban, Francesca Guijarro, Carlos Jimenez-Vicente, Carlos Castillo-Giron, Albert Cortes, Alexandra Martinez-Roca, Ana Triguero, Jose Ramon Alamo, Silvia Bea, Dolors Costa, Dolors Colomer, Maria Rozman, Jordi Esteve, Marina Diaz-Beya

Summary: Despite emerging molecular information, the outcome of patients with chronic myelomonocytic leukemia (CMML) remains unsatisfactory. This study aimed to explore the potential correlation between clinical features, gene mutations, and treatment regimens with overall survival (OS) and transformation into acute myeloid leukemia (AML). The most commonly detected mutations were TET2, SRSF2, ASXL1, and RUNX1. Hypomethylating agents and allogeneic stem cell transplantation (alloSCT) were administered to patients, with varying response rates. Targeted therapies with IDH or FLT3 inhibitors showed promise in specific gene mutation cases. AML transformation occurred in a significant proportion of patients, with changes in gene mutation status observed. Complete molecular characterization can help improve risk stratification and personalize therapy.

CANCERS (2022)

Article Oncology

Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma

Melody Caillot, Hadjer Miloudi, Antoine Taly, Nuria Profitos-Peleja, Juliana C. Santos, Marcelo L. Ribeiro, Elsa Maitre, Simon Saule, Gael Roue, Fabrice Jardin, Brigitte Sola

Summary: By studying the impact of XPO1 gene mutation on protein function, it was found that the mutation renders lymphoma cells more sensitive to SINEs drugs. Additionally, the mutation also leads to mistrafficking of transcription factors between the nucleus and cytoplasm, affecting the response to ibrutinib.

MOLECULAR ONCOLOGY (2023)

Review Pathology

Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation

Birgitta Sander, Elias Campo, Eric D. Hsi

Summary: This manuscript reviews the clinicopathologic and biologic features of chronic lymphocytic leukaemia/small lymphocytic lymphoma, B-cell prolymphocytic leukaemia, and mantle cell lymphoma. Discussions focus on incorporating new knowledge into the next classification system.

VIRCHOWS ARCHIV (2023)

Review Cell Biology

RHOA Therapeutic Targeting in Hematological Cancers

Juliana Carvalho Santos, Nuria Profitos-Peleja, Salvador Sanchez-Vinces, Gael Roue

Summary: Primarily recognized as a regulator of cytoskeletal dynamics, RHOA is involved in regulating various cellular functions. Deregulated RHOA activity has been linked to cancer growth and metastasis. Recent genomic studies have identified RHOA mutations in leukemia/lymphoma, suggesting its dual role as a tumor promoter or suppressor. Targeting RHOA signaling may offer potential therapeutic strategies for cancer. This review summarizes the molecular mechanisms of RHOA in immune regulation and hematological neoplasms, and discusses current strategies for modulating its activity in these diseases.

CELLS (2023)

Article Hematology

Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders

Julia Salmeron-Villalobos, Natalia Castrejon-de-Anta, Pilar Guerra-Garcia, Joan Enric Ramis-Zaldivar, Monica Lopez-Guerra, Sara Mato, Dolors Colomer, Francisco Diaz-Crespo, Javier Menarguez, Marta Garrido-Pontnou, Mara Andres, Eugenia Garcia-Fernandez, Margarita Llavador, Gerard Frigola, Noelia Garcia, Blanca Gonzalez-Farre, Idoia Martin-Guerrero, Carmen Garrido-Colino, Itziar Astigarraga, Alba Fernandez, Jaime Verdu-Amoros, Soledad Gonzalez-Muniz, Berta Gonzalez, Veronica Celis, Elias Campo, Olga Balague, Itziar Salaverria

Summary: This study investigated the molecular features of pediatric monomorphic posttransplant lymphoproliferative disorders (PTLDs) and found shared pathogenesis between PTLD-BL and EBV-positive immunocompetent (IMC) BL.

BLOOD (2023)

Article Oncology

C/EBP & alpha; Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia

Marie Sabatier, Rudy Birsen, Laura Lauture, Sarah Mouche, Paolo Angelino, Jonas Dehairs, Ismael Boussaid, Mael Heiblig, Emeline Boet, Ambrine Sahal, Estelle Saland, Juliana C. Santos, Marc Armengol, Miranda Fernandez-Serrano, Thomas Farge, Guillaume Cognet, Federico Simonetta, Corentin Pignon, Antoine Graffeuil, Celine Mazzotti, Herve Avet-Loiseau, Oceane Delos, Justine Bertrand-Michel, Amelie Chedru, Vilma Dembitz, Paolo Gallipoli, Natasha S. Anstee, Sun Loo, Andrew H. Wei, Martin Carroll, Armelle Goubard, Remy Castellano, Yves Collette, Francois Vergez, Veronique Mansat-De Mas, Sarah Bertoli, Suzanne Tavitian, Muriel Picard, Christian Recher, Nathalie Bourges-Abella, Fanny Granat, Olivier Kosmider, Pierre Sujobert, Benoit Colsch, Carine Joffre, Lucille Stuani, Johannes V. Swinnen, Herve Guillou, Gael Roue, Nawad Hakim, Anne S. Dejean, Petros Tsantoulis, Clement Larrue, Didier Bouscary, Jerome Tamburini, Jean-Emmanuel Sarry

Summary: Although the role of CCAAT-enhancer binding protein α (C/EBPα) in cancer cell and metabolic homeostasis is largely unknown, this study reveals its coordination with FLT3 in lipid anabolism and its regulation of fatty acid biosynthesis and desaturation. Furthermore, FLT3 or C/EBPα inactivation decreases monounsaturated fatty acid incorporation and renders FLT3-mutant AML cells vulnerable to ferroptosis. This finding suggests a promising therapeutic potential for targeting FLT3-mutant AML cells.

CANCER DISCOVERY (2023)

Review Oncology

Novel Tools for Diagnosis and Monitoring of AML

Francesca Guijarro, Marta Garrote, Neus Villamor, Dolors Colomer, Jordi Esteve, Monica Lopez-Guerra

Summary: In recent years, advances in understanding AML pathogenesis and technological progress have led to improved diagnosis and follow-up of AML patients. A combination of immunophenotyping, cytogenetic and molecular studies, including NGS gene panels, is required for AML diagnosis. Multiparametric flow cytometry and quantitative PCR/RT-PCR are currently the most implemented methods for MRD evaluation, but new tools like NGS and digital PCR are needed due to their limitations. This review provides an overview of the technologies used for AML diagnosis and MRD monitoring and highlights the limitations and challenges of current versus emerging tools.

CURRENT ONCOLOGY (2023)

Review Hematology

Epigenetic targets in B- and T-cell lymphomas: latest developments

Marcelo Lima Ribeiro, Salvador Sanchez Vinces, Laura Mondragon, Gael Roue

Summary: Non-Hodgkin's lymphomas (NHLs) are a diverse group of diseases characterized by heterogeneous molecular features and clinical manifestations. Epigenetic dysregulations, including mutations in epigenetic enzymes, are prevalent in both B-cell and T-cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced in clinical management of NHLs.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2023)

Meeting Abstract Oncology

Loss of RHOA impairs lenalidomide antitumor activity in mantle cell lymphoma

J. Carvalho Santos, N. Profitos Peleja, M. Caillot, S. Sanchez Vinces, B. Sola, M. Lima Ribeiro, G. Roue

EUROPEAN JOURNAL OF CANCER (2022)

No Data Available